drugset
Drugs / DFV890
last change Dec 2024 re-read 9 days ago

DFV890

targets NLRP3 via inhibition

Developed for
coronary artery disorder · clonal hematopoiesis of indeterminate potential · familial cold autoinflammatory syndrome · myeloid neoplasm · osteoarthritis, knee · pneumonia
Investigated by
Novartis Pharmaceuticals

Trials 6

today NCT06097663 · Ph 2 NCT06031844 · Ph 2 NCT05552469 · Ph 1 NCT04868968 · Ph 2 NCT04886258 · Ph 2 NCT04382053 · Ph 2
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05552469 May 2023 → Feb 2027 expected myeloid neoplasm Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 25 trials · 2 met primary · 2 missed
Phase 2 NCT06097663 Feb → Oct 2024 clonal hematopoiesis of indeterminate potential, coronary artery disorder Novartis Pharmaceuticals Completed Met primary
Phase 2 NCT06031844 Oct 2023 → Dec 2024 coronary artery disorder Novartis Pharmaceuticals Completed Met primary
Phase 2 NCT04868968 Sep 2021 → Dec 2022 familial cold autoinflammatory syndrome Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT04886258 Sep 2021 → Dec 2024 osteoarthritis, knee Novartis Pharmaceuticals Completed Missed primary
Phase 2 NCT04382053 May → Dec 2020 pneumonia Novartis Pharmaceuticals Completed Missed primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as DFV890 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04886258 ↗
5

NCT04382053 ↗

NCT04868968 ↗

NCT05552469 ↗

NCT06097663 ↗

NCT06031844 ↗
Action Inhibit “DFV890: a new oral NLRP3 inhibitor” PMID 36104613 ↗ Sep 2022
Route Oral “orally/nasogastrically administered” NCT04382053 ↗
Route Other “orally/nasogastrically administered” NCT04382053 ↗
Target NLRP3 “DFV890: a new oral NLRP3 inhibitor” PMID 36104613 ↗ Sep 2022